This information was published on 2025-06-03T09:17:52 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2472435 (IR 1803143) |
| (220) |
23 Apr 2024
|
| (300) |
US, 22 Apr 2024, 98513070
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immunological disorders; pharmaceutical preparations for the treatment of auto-immune disorders; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of graft versus host disorder (GVHD); pharmaceutical preparations for the treatment of hematological disorders; pharmaceutical preparations for the treatment of myeloproliferative disorders; pharmaceutical preparations for the treatment of skeletal or chondrocyte disorders; pharmaceutical preparations for the treatment of dermatological disorders. Class 42 Scientific and medical research relating to oncological, viral, hematological, auto-immune, graft versus host, inflammatory, metabolic, myeloproliferative, skeletal or chondrocyte and dermatological disorders. |
| (540) | INCYTE |
| (550) | Word |
| (730) |
Incyte Holdings Corporation
|
| (750) |
Minter Ellison Rudd Watts
|
Find out more about publications on the About page.